Organisation paid for research Program year 2025 Source: CMS Open Payments

Aara Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$89,001

119 payments

Through program year 2025, Aara Clinical Research is reported as receiving $89,001 in research payments, across 119 payments.

By program year

2 rows

Year	Kind	Amount	Payments
2025	Research	$50,142	101
2024	Research	$38,859	18

Breakdown

Who paid Research payments · program years 2024–2025

Eli Lilly and Company $63,601 34 payments
Argenx US, Inc. $13,977 79 payments
Ucb SA $11,423 6 payments

Studies the money was for Research payments · program years 2024–2025

Efficacy and Safety of Ixekizumab Or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Active Psoriatic Arthritis and Obesity Or Overweight: A Phase 3B, Randomized, Multicenter, Open-Label Study (Together-Psa) $48,742 28 payments
A Phase 2A, Single-Arm Study to Investigate the Efficacy and Safety of Ly3541860 in Adult Participants With Moderately-To-Severely Active Rheumatoid Arthritis $14,859 6 payments
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome $13,977 79 payments
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus $9,287 3 payments
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. $2,084 2 payments
A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Dapirolizumab Pegol Treatment in Study Participants With Systemic Lupus Erythematosus $53 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.